At 10 years, more than one-third (34.0%) of patients with advanced melanoma were alive after treatment with KEYTRUDA, compared to 23.6% of patients treated with ipilimumab
Total investment incurred for setting up the new R&D Rs 250 crore
The acquisition is based on an enterprise value of Rs. 1,660 crore
Increases efficiency by 70% compared to stainless steel or glass manufacturing methods
Investment in new plant meets increasing demand for functional excipients for oral drug delivery
Objective response rate of 54.8% seen with Daiichi Sankyo and Merck’s ifinatamab deruxtecan at 12 mg/kg dose in pretreated patients
Ami informs that PMDA Japan has issued Inspection Result Report declaring the Sachin facility as a Good Manufacturing Practices (GMP) compliant.
Lilly will license certain baricitinib manufacturing know-how to enable EVA Pharma to manufacture and supply treatment for various immunological diseases
The companies will combine Nanoform’s Biologics platform with the Celanese VitalDose Drug Delivery platform to further optimize controlled release of biologics
Chobhe brings over 30 years of extensive experience in quality and regulatory management within the pharmaceutical industry
Subscribe To Our Newsletter & Stay Updated
